A detailed history of Pfm Health Sciences, LP transactions in Erasca, Inc. stock. As of the latest transaction made, Pfm Health Sciences, LP holds 4,876,911 shares of ERAS stock, worth $11.6 Million. This represents 0.78% of its overall portfolio holdings.

Number of Shares
4,876,911
Previous 4,671,774 4.39%
Holding current value
$11.6 Million
Previous $11 Million 20.75%
% of portfolio
0.78%
Previous 0.57%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.17 - $3.28 $445,147 - $672,849
205,137 Added 4.39%
4,876,911 $13.3 Million
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $3.82 Million - $5.62 Million
2,136,672 Added 84.28%
4,671,774 $11 Million
Q1 2024

May 14, 2024

SELL
$1.67 - $2.55 $67,483 - $103,042
-40,409 Reduced 1.57%
2,535,102 $5.22 Million
Q4 2023

Feb 14, 2024

SELL
$1.67 - $2.49 $2.26 Million - $3.37 Million
-1,355,122 Reduced 34.48%
2,575,511 $5.49 Million
Q3 2023

Nov 14, 2023

SELL
$1.97 - $2.91 $1.71 Million - $2.52 Million
-866,827 Reduced 18.07%
3,930,633 $7.74 Million
Q4 2022

Feb 14, 2023

SELL
$3.89 - $8.57 $9.6 Million - $21.1 Million
-2,467,521 Reduced 33.96%
4,797,460 $20.7 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $8.05 Million - $14.8 Million
1,383,599 Added 23.53%
7,264,981 $56.7 Million
Q2 2022

Aug 15, 2022

BUY
$4.58 - $8.72 $4.99 Million - $9.5 Million
1,089,976 Added 22.75%
5,881,382 $32.8 Million
Q1 2022

May 16, 2022

SELL
$8.6 - $15.48 $3.44 Million - $6.19 Million
-399,999 Reduced 7.71%
4,791,406 $41.2 Million
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $90.5 Million - $126 Million
5,191,405 New
5,191,405 $98.2 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $289M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.